We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$529M
1-Year Est. Return
337.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.21%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$340M
AUM Growth
-$182M
(-35%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-55.94%
Top 10 Holdings %
Top 10 Hldgs %
58.11%
Holding
39
New
6
Increased
3
Reduced
19
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ORKA
Oruka Therapeutics
ORKA
|
+$17.9M |
| 2 |
ProMIS Neurosciences
PMN
|
+$4.17M |
| 3 |
Viridian Therapeutics
VRDN
|
+$4.09M |
| 4 |
Unicycive Therapeutics
UNCY
|
+$3.44M |
| 5 |
Cartesian Therapeutics
RNAC
|
+$3.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$31.9M |
| 2 |
ACLX
Arcellx
ACLX
|
+$26.1M |
| 3 |
Evolus
EOLS
|
+$17.9M |
| 4 |
Insmed
INSM
|
+$16.8M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.54% |
| 2 | Miscellaneous | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Unicycive Therapeutics
UNCY
$131M
| $3.49M | 1.03% |
+855,900
| New | +$3.44M |
|
|
27
ProMIS Neurosciences
PMN
$116M
| $3.49M | 1.03% |
+111,628
| New | +$4.17M |
|
|
28
Cartesian Therapeutics
RNAC
$239M
| $3.22M | 0.95% |
+200,000
| New | +$3.12M |
|
29
VistaGen Therapeutics
VTGN
$10.5M
| $2.03M | 0.6% |
674,075
-855,263
| -56% | -$2.92M |
|
|
CLYM
30
Climb Bio
CLYM
$799M
| $1.26M | 0.37% |
+248,168
| New | +$1.76M |
|
31
AnaptysBio
ANAB
$1.62B
| – | – |
-25,000
| Closed | -$627K |
|
|
ESPR
32
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-5,791,594
| Closed | -$12.9M |
|
|
FOLD
33
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-1,495,500
| Closed | -$14.8M |
|
|
34
Insmed
INSM
$26.2B
| – | – |
-250,000
| Closed | -$16.8M |
|
35
Lexicon Pharmaceuticals
LXRX
$894M
| – | – |
-30,000
| Closed | -$50.4K |
|
36
Puma Biotechnology
PBYI
$477M
| – | – |
-1,486,544
| Closed | -$4.85M |
|
37
Spyre Therapeutics
SYRE
$8.02B
| – | – |
-134,612
| Closed | -$3.16M |
|
|
TERN
38
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-1,149,406
| Closed | -$7.83M |
|
39
Kyverna Therapeutics
KYTX
$430M
| – | – |
-499,152
| Closed | -$3.74M |
|
Similar funds
KMWM
FFIC
TA
JDLA
CCG
DAS
VAMG
CWM
Great Point Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Great Point Partners held 39 positions worth $340M, down 35% from $522M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Great Point Partners withdrew a net $190M in Q3 2024, closing 9 positions and reducing 19 holdings. Its most notable exit was Insmed, an estimated $16.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Great Point Partners opened a new position in Oruka Therapeutics worth $12.6M.
- Great Point Partners's largest Q3 2024 buy was Oruka Therapeutics: 514,659 shares worth $12.6M.
- Great Point Partners added most to Viridian Therapeutics in Q3 2024, an estimated $4.09M increase.
- Great Point Partners's biggest Q3 2024 reduction was UroGen Pharma, cutting an estimated $31.9M.
- Great Point Partners fully exited Insmed in Q3 2024, selling an estimated $16.8M.
- Great Point Partners's ten largest holdings make up 58% of its $340M portfolio in Q3 2024.
- Great Point Partners opened 6 new positions and closed 9 in Q3 2024.
- Great Point Partners's portfolio value fell 35% quarter-over-quarter to $340M.
Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.